ARTICLE | Product Development
While the Phase II data at CTAD cast doubt on UCB’s bepranemab, they represent a critical advance for the field
By Selina Koch, Executive Editor
November 1, 2024 9:18 PM UTC
Roche may not have seen enough promise in anti-tau mAb bepranemab to take it forward in Alzheimer’s disease, but Phase II data presented by former partner UCB provide some of the first clues about what species of tau to target and in which patients.
With the validation of β-amyloid as a modestly effective target for early Alzheimer’s disease, many companies have set their sights next on tau…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654043/a-tau-mab-has-achieved-target-clearance-in-alzheimer-s-patients